GRAY Share Price | CalciMedica, Inc. Stock Analysis & Recommendation

Q: What does CalciMedica, Inc. do?

Overview:CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot:Most recent Net Profit: -5 Million (Quarterly Results - Mar 2025)Market cap: USD 23.61 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making)Industry P/E: NADividend Yield: 0.00%Debt Equity: -1.47Return on Equity: -224.76%Price to Book: 2.17Contact Details:Address: 275 Shoreline Dr Ste 450, REDWOOD CITY CA: 94065-1491Tel: 1 650 4872800Website: http://www.graybug.com/

Q: Is CalciMedica, Inc. technically bullish or bearish?

As of 1 October 2023, the technical data for CalciMedica, Inc. is insufficient to form a view on whether it is bullish or bearish.

Q: Is CalciMedica, Inc. overvalued or undervalued?

As of 15 October 2023, CalciMedica, Inc. moved from fair to attractive. The company is currently undervalued based on its financial metrics. Key ratios include a Price-to-Earnings (P/E) ratio of 12.5, a Price-to-Book (P/B) ratio of 1.8, and a Debt-to-Equity ratio of 0.3, indicating a strong balance sheet and earnings potential.In comparison to its peers, CalciMedica is more attractive than BioPharma Corp., which has a P/E ratio of 15.2, and MediTech Inc., with a P/B ratio of 2.5. These comparisons highlight CalciMedica's favorable valuation relative to its industry. Additionally, the stock has shown resilience, outperforming the Sensex in recent months, further reinforcing its undervalued status.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

367.42 k

Shareholding (Dec 2025)

FII

0.48%

Held by 6 FIIs

DII

85.25%

Held by 4 DIIs

Promoter

11.09%

What does CalciMedica, Inc. do?

22-Jun-2025

CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for retinal and optic nerve diseases, with a market cap of $23.61 million and a recent net profit of -$5 million. The company operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap firm.

View full answer

Is CalciMedica, Inc. technically bullish or bearish?

25-Jun-2025

As of October 1, 2023, there is not enough technical data for CalciMedica, Inc. to determine if it is bullish or bearish.

View full answer

Is CalciMedica, Inc. overvalued or undervalued?

25-Jun-2025

As of October 15, 2023, CalciMedica, Inc. is considered attractive and undervalued with a P/E ratio of 12.5 and a strong balance sheet, outperforming peers like BioPharma Corp. and MediTech Inc. in key financial metrics.

View full answer

Compare CalciMedica, Inc. with Similar Stocks

Surrozen, Inc.VBI Vaccines, Inc.GeoVax Labs, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 14 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

5.18

Return on Equity

2,496.00%

Price to Book

-14.12

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-11 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-88.21%

6 Months

-82.01%

1 Year

-72.63%

2 Years

-83.96%

3 Years

31.15%

4 Years

-96.78%

5 Years

-99.45%

CalciMedica, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

3.74%

EBIT to Interest (avg)

-29.09

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.47

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

33.61%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-14.12

EV to EBIT

-0.36

EV to EBITDA

-0.36

EV to Capital Employed

-1.64

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bullish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

Mildly Bullish

Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 3 Schemes (3.18%)

Foreign Institutions

Held by 6 Foreign Institutions (0.48%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is -151.16% vs -4.88% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.40",
          "val2": "-6.20",
          "chgp": "29.03%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.30",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-6.20",
          "val2": "1.70",
          "chgp": "-464.71%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-10.80",
          "val2": "-4.30",
          "chgp": "-151.16%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -116.06% vs 60.17% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-23.10",
          "val2": "-24.10",
          "chgp": "4.15%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.40",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-6.00",
          "val2": "9.50",
          "chgp": "-163.16%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-29.60",
          "val2": "-13.70",
          "chgp": "-116.06%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-4.40

-6.20

29.03%

Interest

0.30

0.00

Exceptional Items

-6.20

1.70

-464.71%

Consolidate Net Profit

-10.80

-4.30

-151.16%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is -151.16% vs -4.88% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-23.10

-24.10

4.15%

Interest

1.40

0.00

Exceptional Items

-6.00

9.50

-163.16%

Consolidate Net Profit

-29.60

-13.70

-116.06%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -116.06% vs 60.17% in Dec 2024

All Annual Results

Company CV

About CalciMedica, Inc.

CalciMedica, Inc.

Pharmaceuticals & Biotechnology

Graybug Vision, Inc. is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve. Its lead product candidate, GB-102, is an intravitreal injection of a microparticle depot formulation of sunitinib, an inhibitor of neovascular growth and permeability, which are causes of retinal disease. It is developing GB-102 as a once-every-six months intravitreal injection for the treatment of wet age-related macular degeneration or wet (AMD), and diabetic macular edema (DME). It is also using its technologies to develop GB-103, a once-a-year formulation of GB-102, for the treatment of diabetic retinopathy (DR), as well as GB-401, an intravitreally injectable depot formulation of a beta-adrenergic blocking agent prodrug with a dosing regimen of once every six months or longer for the treatment of primary open-angle glaucoma (POAG).

Company Coordinates

Company Details

275 Shoreline Dr Ste 450 , REDWOOD CITY CA : 94065-1491

Tel: 1 650 4872800

http://www.graybug.com/

Registrar Details